However, there are some presumptions that 5-HT2A agonists might be worthy of consideration in schizophrenia therapy, especially when negative symptoms and cognitive deficits are predominant in the features of the disorder [108], and these deficits are associated with structural brain changes, i.e., significant cortical thinning [109–111], reduction gray matter volume [112], reduction in synaptic proteins and synaptic loss [33, 113]. The gene discussed is HTR2A; the disease is schizophrenia.